Celldex Therapeutics Inc $13.50

up +0.41


29/7/2014 12:19 PM  |  NASDAQ : CLDX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get CLDX Trend Analysis - it has underperformed the S&P 500 by 52%

Partner Headlines

  1. 5-Star Biotech Stock Watch: Celldex Therapeutics

    Benzinga
  2. Top Healthcare Movers For June 9, 2014

    Benzinga
  3. Mid-Afternoon Market Update: Markets Head Downward As Commodities Continue ...

    Benzinga
  4. Celldex's Phase 1 Study of CDX-1401 Published in Science Translational ...

    Benzinga
  5. Mid-Afternoon Market Update: Markets Recover Slightly As Healthcare Stocks ...

    Benzinga
  6. Mid-Day Market Update: NASDAQ Tumbles 1.65%; Nu Skin Shares Surge After ...

    Benzinga
  7. Mid-Morning Market Update: Markets Mostly Lower; ReneSola Swings To Q4 ...

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Earnings Scheduled For March 3, 2014

    Benzinga
  10. Trade of the Day: Long CLDX

    Benzinga
  11. Celldex Therapeutics Prices 7M Share Offering at $24.50/Share

    Benzinga
  12. Celldex Therapeutics Announces 6.5M Share Offering

    Benzinga
  13. Celldex Therapeutics Initiates Accelerated Approval Study of Glembatumumab ...

    Benzinga
  14. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga
  15. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive ...

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Celldex Therapeutics Presents Positive Phase 2 Rindopepimut Data in Patients ...

    Benzinga
  18. Downside Protection For Regeneron Pharmaceuticals

    Benzinga
  19. Celldex Announces Publication of Preliminary Data from Phase 2 ReACT Study ...

    Benzinga
  20. Mid-Afternoon Market Update: Twitter IPO a Wild Success as Markets Slide

    Benzinga
  21. Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor ...

    Benzinga
  22. Celldex to Present Dat at SITC, SNO Annual Meetings

    Benzinga
  23. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga
  24. Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

    Benzinga
  25. Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

    Benzinga
  26. These ETFs House The Next Biotech Takeover Targets

    Benzinga
  27. Mid-Day Market Update: Sysco Drops On Q4 Results, McEwen Mining Shares ...

    Benzinga
  28. Mid-Morning Market Update: US Markets Mixed, BlackBerry To Explore Strategic ...

    Benzinga
  29. Celldex Announces Expansion of Phase 2 ReACT Study in Recurrent Glioblastoma ...

    Benzinga
  30. Celldex Reports Phase 1 Study Results of CDX-301, Says Data Support Starting ...

    Benzinga
  31. Celldex Therapeutics Announces Full Exercise of Underwriters' Option to ...

    Benzinga
  32. Celldex's CDX-301 Safely Mobilizes Hematopoietic Cells in Phase 1 Study

    Benzinga
  33. UPDATE: Oppenheimer Raises PT to $10 on Celldex Therapeutics on Improved ...

    Benzinga
  34. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex ...

    Benzinga
  35. Morning Market Movers

    Benzinga
  36. Benzinga's Top Pre-Market Gainers

    Benzinga
  37. Celldex Posts Positive 3-Year Survival Data from Phase 2 Rindopepimut Program

    Benzinga
  38. CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q)

    GuruFocus
  39. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex ...

    Benzinga
  40. UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on Celldex Therapeutics

    Benzinga
  41. Earnings Scheduled For August 10, 2012

    Benzinga
  42. Social Media Outlook for Thursday May 24 (HNZ, PAY, RIMM, NTAP)

    Benzinga
  43. From Yesterday, Celldex's CDX-011 Demonstrates High Response Rates in Patients ...

    Benzinga
  44. Celldex Therapeutics Added to Nasdaq Biotechnology Index

    Benzinga
  45. Notable Put Options Activity in Celldex Therapeutics

    Benzinga
  46. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  47. Notable Put Options Activity in Celldex Therapeutics

    Benzinga
  48. Benzinga's Microcap Movers for Tuesday January 17, 2012

    Benzinga
Trading Center